SLC30A1 and Alzheimer disease: ZnT1 was found to be decreased significantly in the hippocampus of subjects with the precursor states MCI (a stage from which 95% of progress to develop dementia) and pre-clinical AD (PCAD; where subjects have no overt clinical manifestations of AD but pathology is revealed post-mortem), as well as in AD [3], [4].